Success Metrics

Clinical Success Rate
90.5%

Based on 19 completed trials

Completion Rate
90%(19/21)
Active Trials
9(18%)
Results Posted
21%(4 trials)
Terminated
2(4%)

Phase Distribution

Ph phase_3
3
6%
Ph phase_4
3
6%
Ph not_applicable
4
8%
Ph phase_1
4
8%
Ph phase_2
3
6%

Phase Distribution

4

Early Stage

3

Mid Stage

6

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
4(23.5%)
Phase 2Efficacy & side effects
3(17.6%)
Phase 3Large-scale testing
3(17.6%)
Phase 4Post-market surveillance
3(17.6%)
N/ANon-phased studies
4(23.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.6%

19 of 23 finished

Non-Completion Rate

17.4%

4 ended early

Currently Active

9

trials recruiting

Total Trials

51

all time

Status Distribution
Active(9)
Completed(19)
Terminated(4)
Other(19)

Detailed Status

Completed19
unknown19
Active, not recruiting5
Recruiting4
Terminated2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
51
Active
9
Success Rate
90.5%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (23.5%)
Phase 23 (17.6%)
Phase 33 (17.6%)
Phase 43 (17.6%)
N/A4 (23.5%)

Trials by Status

active_not_recruiting510%
recruiting48%
terminated24%
completed1937%
withdrawn24%
unknown1937%

Recent Activity

Clinical Trials (51)

Showing 20 of 51 trialsScroll for more
NCT05313087

COVID-19 Vaccine Response in Chronic Respiratory Conditions

Completed
NCT05160636

A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza

Active Not Recruiting
NCT05415267Phase 3

Immunosuppression and COVID-19 Boosters

Recruiting
NCT04977024Phase 2

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

Active Not Recruiting
NCT05919472Not Applicable

Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women

Completed
NCT06178991Phase 3

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

Completed
NCT04659759

COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes

Completed
NCT06864143Phase 2

A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

Completed
NCT04705116

COVID-19 Vaccines International Pregnancy Exposure Registry

Recruiting
NCT06355232Phase 1

Covid-19 and Influenza Oral Vaccine Study

Recruiting
NCT06683352Phase 1

A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People

Completed
NCT04889274Phase 1

Investigation of the Effects of Dietary Nitrate and Sex on COVID-19 Vaccine Induced Vascular Dysfunction in Healthy Men and Women (DiNOVasc-COVID-19)

Active Not Recruiting
NCT05584735

Determining the Relationship Between Gut Microbiota and Immune Response to Influenza or COVID-19 Vaccine

Completed
NCT06097273Phase 3

A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

Completed
NCT05286242

Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients

Active Not Recruiting
NCT05019456Not Applicable

Exercise and COVID-19 Viral T-cell Immunity

Active Not Recruiting
NCT05139992

COVID-19 Vaccine Response in Sickle Cell Disease

Completed
NCT04922944

Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients

Completed
NCT04706390

Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination

Recruiting
NCT04770649

Vaccine Observation to Include All Communities for Equitable Science

Terminated

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
51